NASDAQ
13.98USD
+0.60 (+4.48%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
4.3B
P/E
—
EPS
—
Beta
0.73
52W range
1.21-24.28
Day range
13.42–14.74
Open
13.43
Prev close
13.38
Volume
4.4M
Avg volume
6.8M
Dividend
0.00
IPO
2021-07-16
https://www.newsfilecorp.com/release/301404/ROSEN-LEADING-INVESTOR-COUNSEL-Encourages-TruBridge-Inc.-Investors-to-Inquire-About-Securities-Class-Action-Investigation-TBRG · 6/14/2026-0.80
https://www.newsfilecorp.com/release/301301/ERAS-EQUITY-ACTION-REMINDER-Faruqi-Faruqi-LLP-Reminds-Erasca-ERAS-Investors-of-Securities-Class-Action-Lawsuit-Deadline-on-August-10-2026 · 6/13/2026-1.00
https://www.globenewswire.com/news-release/2026/06/02/3305720/0/en/Bragar-Eagel-Squire-P-C-is-Investigating-Erasca-Inc-NASDAQ-ERAS-on-Behalf-of-Erasca-Stockholders-and-Encourages-Investors-to-Contact-the-Firm.html · 6/2/2026-0.80
https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-mimedx-group-inc---mdxg-302779487.html · 5/21/2026
https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-erasca-inc---eras-302779485.html · 5/21/2026-1.00
https://www.marketbeat.com/instant-alerts/erasca-touts-eye-popping-eras-0015-lung-cancer-data-fda-path-at-bofa-conference-2026-05-16/ · 5/16/2026+0.80
https://www.globenewswire.com/news-release/2026/05/14/3295477/0/en/ERASCA-INVESTOR-ALERT-Bragar-Eagel-Squire-P-C-is-Investigating-Erasca-Inc-on-Behalf-of-Erasca-Stockholders-and-Encourages-Investors-to-Contact-the-Firm.html · 5/14/2026-0.80
https://www.globenewswire.com/news-release/2026/05/10/3291521/0/en/ERAS-Investors-Have-Opportunity-to-Join-Erasca-Inc-Fraud-Investigation-with-the-Schall-Law-Firm.html · 5/10/2026-1.00
https://www.globenewswire.com/news-release/2026/05/10/3291520/0/en/CHKP-Investors-Have-Opportunity-to-Join-Check-Point-Software-Technologies-Ltd-Fraud-Investigation-with-the-Schall-Law-Firm.html · 5/10/2026-1.00
https://seekingalpha.com/article/4894762-erasca-inc-eras-discusses-preliminary-phase-i-data-and-differentiation-of-pan-ras-molecular · 4/28/2026+0.60
https://www.newsfilecorp.com/release/290366/ROSEN-A-LEADING-INVESTOR-RIGHTS-LAW-FIRM-Encourages-monday.com-Ltd.-Investors-to-Secure-Counsel-Before-Important-Deadline-in-Securities-Class-Action-MNDY · 3/30/2026-0.80
https://www.newsfilecorp.com/release/290407/MREO-FINAL-DEADLINE-ROSEN-LONGSTANDING-INVESTOR-COUNSEL-Encourages-Mereo-BioPharma-Group-plc-Investors-with-Losses-in-Excess-of-100K-to-Secure-Counsel-Before-Important-April-6-Deadline-in-Securities-Class-Action-MREO · 3/30/2026-0.80
Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme. The company was founded in 2018 and maintains its headquarters in San Diego, California.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
